What Researchers Did
Researchers evaluated the safety and efficacy of intravenous tenoxicam for postoperative pain relief in 80 patients undergoing cesarean delivery.
What They Found
Researchers found that intravenous tenoxicam significantly prolonged analgesia to 365 minutes compared to 305 minutes in the control group (P < .001) and significantly decreased supplementary analgesic requirements from 2.25 to 1.55 doses. Adverse side effects were similar between groups, and neonatal Apgar scores and blood gas analyses showed no differences.
What This Means for Canadian Patients
For Canadian patients undergoing cesarean delivery, intravenous tenoxicam could offer a modest increase in the duration of postoperative pain relief and reduce the need for additional pain medication. This could potentially lead to improved comfort and a smoother recovery period after surgery.
Canadian Relevance
This study was not conducted in Canada and does not have direct Canadian relevance.
Study Limitations
As a preliminary report, this study's findings may be limited by its relatively small sample size and require further investigation in larger, multi-center trials.